Medicus Pharma LTD S-1 registration statements

Medicus Pharma Ltd. files S-1 for the resale of up to 2.68 million common shares by a selling shareholder, highlighting ongoing clinical trials and significant financial losses.

Medicus Pharma Ltd. filed an S-1 registration statement for the resale of up to 1,397,184 common shares by selling shareholders following its acquisition of Antev Limited and its Teverelix drug candidate.

Medicus Pharma Ltd. details ongoing clinical trials for SkinJectTM and Teverelix, recent capital raises, and significant operating losses, raising going concern doubts.

Medicus Pharma Ltd., a clinical-stage biotech company, has filed an S-1 registration statement for a public offering of up to 1,375,000 units, aiming to raise approximately $10 million to fund its Phase 2 clinical trials for basal cell carcinoma and support general corporate purposes, despite ongoing operating losses and a 'going concern' warning from its auditor.

Medicus Pharma Ltd., a clinical-stage biotech company, has filed an S-1 registration statement to allow for the resale of up to 3.71 million common shares by a selling shareholder, while also disclosing significant operating losses, a going concern warning, and updates on its lead skin cancer drug candidate and a new acquisition.